Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -2882.46% is 463% below its 4-year average of -512.02%, around the middle of its 4-year range (-8041.23%–33.94%).
37.35% above its 12-month average of -4600.98%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2024 (2024-12-31): -8041.23%.
EBITDA MARGIN
-2882.46%
EBITDA MARGIN AVG TTM
-4600.98%
EBITDA MARGIN AVG 3Y
-2258.96%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+37.35%
CURRENT VS 3Y AVG
-27.60%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SAB Biotherapeutics, Inc.
Market Cap
$270.41M
EBITDA Margin
-2882.46%
TTM Avg
-4600.98%
3Y Avg
-2258.96%
5Y Avg
N/A
Market Cap
$271.00M
EBITDA Margin
-2082.59%
TTM Avg
-1743.06%
3Y Avg
-1015.79%
5Y Avg
-806.48%
Market Cap
$270.61M
EBITDA Margin
-64.44%
TTM Avg
-40.40%
3Y Avg
-20.73%
5Y Avg
-9.01%
Market Cap
$271.28M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$270.20M
EBITDA Margin
-20.52%
TTM Avg
-21.55%
3Y Avg
-22.69%
5Y Avg
-17.32%
Market Cap
$270.00M
EBITDA Margin
-58.29%
TTM Avg
-89.32%
3Y Avg
-189.95%
5Y Avg
-208.07%
Market Cap
$264.74M
EBITDA Margin
-7643.91%
TTM Avg
-11162.31%
3Y Avg
-5581.16%
5Y Avg
-3720.77%
Market Cap
$264.52M
EBITDA Margin
-768.62%
TTM Avg
-551.06%
3Y Avg
-374.75%
5Y Avg
-290.29%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | $270.41M | -2882.46% | -4600.98% | -2258.96% | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $271.00M | -2082.59% | -1743.06% | -1015.79% | -806.48% |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $270.61M | -64.44% | -40.40% | -20.73% | -9.01% |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $271.28M | N/A | N/A | N/A | N/A |
| Treace Medical Concepts, Inc. (TMCI)vs › | $270.20M | -20.52% | -21.55% | -22.69% | -17.32% |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $270.00M | -58.29% | -89.32% | -189.95% | -208.07% |
| Scribe Therapeutics Inc. (SCTX)vs › | $269.43M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.74M | -7643.91% | -11162.31% | -5581.16% | -3720.77% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $264.52M | -768.62% | -551.06% | -374.75% | -290.29% |
| OraSure Technologies, Inc. (OSUR)vs › | $261.82M | -50.56% | -27.90% | -8.82% | -5.54% |
Gross Margin
0.0%
EBITDA Margin
-2882.5%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2024-12-31 | -8041.23% |
| 2024-06-30 | -3488.56% |
| 2024-03-31 | -995.78% |
| 2023-12-31 | -5878.35% |
| 2023-09-30 | -342.35% |
| 2023-06-30 | -6530.03% |
| 2023-03-31 | -1114.92% |
| 2022-12-31 | -321.00% |
| 2022-09-30 | -192.14% |
| 2022-06-30 | -91.23% |
| 2022-03-31 | -51.09% |
| 2021-12-31 | -60.81% |
| 2021-09-30 | -24.38% |
| 2021-06-30 | -14.35% |
| 2021-03-31 | 6.45% |
| 2020-12-31 | 33.94% |
